Flumazenil is a competitive pharmacologic antagonist of benzodiazepine (BZD) agonists at BZD receptor sites. It is approved by the Food and Drug Administration (FDA) for reversal of BZD‐associated conscious sedation and BZD overdoses when administered only by the intravenous route. If administered in sufficient dose to overpower the effects of the BZD agonist overdose by competitively displacing the agonist from its BZD receptor sites, and if in an acute emergency sufficient flumazenil reaches those receptor sites quickly enough to reverse the unconsciousness before hypoxic brain damage from hypoventilation, upper airway obstruction, or apnea occurs, the drug can be lifesaving. Typically